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Abstract: The tripartite motif (TRIM) protein family is attracting increasing interest in oncology.
As a protein family based on structure rather than function, a plethora of biological activities are
described for TRIM proteins, which are implicated in multiple diseases including cancer. With
hormone-driven cancers being among the leading causes of cancer-related death, TRIM proteins have
been described to portrait tumor suppressive or oncogenic activities in these tumor types. This review
describes the biological impact of TRIM proteins in relation to hormone receptor biology, as well as
hormone-independent mechanisms that contribute to tumor cell biology in prostate, breast, ovarian
and endometrial cancer. Furthermore, we point out common functions of TRIM proteins throughout
the group of hormone-driven cancers. An improved understanding of the biological impact of TRIM
proteins in cancer may pave the way for improved prognostication and novel therapeutics, ultimately
improving cancer care for patients with hormone-driven cancers.
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1. Introduction
The tripartite motif (TRIM) protein family represents a class of ubiquitously expressed
proteins that have different roles in many cellular mechanisms and molecular pathways [1].
The tripartite structure is exclusive to metazoans and has been maintained with few changes
throughout evolution. Whilst only a few TRIM genes are present in invertebrates (the
fruit fly Drosophila melanogaster possesses seven TRIM genes), a large expansion occurred
with the evolution of vertebrates and especially in mammals, with 60 to 70 TRIM genes in
mouse, rat, dog, cat and cow [2,3]. In humans, there are over 80 known TRIM genes [4]
that encode proteins that share a similar structure referred to as the RBCC motif. This
conserved structure consists of an N-terminal RING (Really Interesting New Gene) domain,
adjacent to either one or two cysteine/histidine-rich motifs known as B-boxes (B1 and
B2), followed by an alpha-helical coiled-coil region (CC) [5,6]. Eight TRIM proteins stand
out for not having a RING domain [4]. In general, TRIMs differ from each other in their
C-terminus and in their overall domain structure. According to their C-terminus and
domain organization, TRIMs have been classified into eleven subfamilies, C-I to C-XI [7].
Most TRIM proteins have been defined as E3s based on the presence of the RING
domain [8], which is responsible for the recruitment of E2 enzymes carrying ubiquitin [9].
Aided by the B boxes to enhance target recognition, the CC region is necessary for the
interaction with TRIM family members and other proteins. Indeed, many groups have
reported that TRIM proteins form homo- and hetero-interactions (dimers or oligomers)
through the interplay between CC regions [10–13]. The C-terminal domain allows high
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specificity for substrate recruitment and scaffold and can also have enzymatic activity or
chromatin binding capacity [14].
2. TRIMs: Cellular Processes and Mechanisms
TRIM proteins regulate a high variety of cellular mechanisms, including cell cy-
cle progression, apoptosis, gene expression, chromatin remodeling, signal transduction,
metabolism, neurogenesis and stem cell biology (activities comprehensively reviewed
in [15–19]). They are also involved in physiological and pathophysiological processes,
including development, carcinogenesis and host defense against viral pathogens [15–17].
TRIM proteins are often involved in the aforementioned cellular functions as E3 proteins,
as part of the so-called ubiquitin cycle [20]. Ubiquitination is a common post-translational
modification to control cellular processes, including cell cycle, genome integrity, cell death,
inflammatory signaling and defense against pathogens [21]. In this context, E3 ubiquitin
ligases, including numerous TRIMs, are necessary for the transfer of ubiquitin from E2
ubiquitin-conjugating enzymes to target proteins in the last step of the ubiquitin cycle [22].
E3s are also responsible for the recognition of target proteins and thus for the efficacy and
selectivity of the system [23].
Similar to ubiquitination, it has been reported that some TRIMs can control cellu-
lar processes by adding ubiquitin-like proteins, such as SUMO [24], ISG15 [25,26] and
NEDD8 [27].
In addition to the canonical E3 ligase function, TRIM proteins mediate their cel-
lular roles through other mechanisms, including the elimination of misfolded proteins,
exerted through different pathways, including autophagy and the endoplasmic reticulum-
associated degradation [28,29].
3. Steroid Hormone Receptors
The steroid hormone receptor (SHR) family includes the estrogen receptor (ER), an-
drogen receptor (AR), progesterone receptor (PR), glucocorticoid receptor and mineralo-
corticoid receptor. SHRs are also referred to as type I nuclear receptors, which represent
a subfamily of the larger nuclear receptor family that also includes receptors for thyroid
hormone, retinoids and nonsteroidal ligands [30,31]. SHRs affect development, cell dif-
ferentiation, homeostasis, reproduction and metabolism and are associated with several
human diseases, including hormone-driven cancers [32]. For example, the role of the ER
in breast cancer (BC) cell proliferation, survival and tumorigenesis is well documented
and 75% of BC cases are ERα positive [33,34]. Similarly, the AR plays a crucial role in the
development and progression of prostate cancer (PC), being a modulator of proliferation,
apoptosis, migration and invasion of PC cells [35].
SHRs are transcription factors that share a similar and highly conserved structure
and possess common functional features centered around the activation function (AF)
domains that facilitate transcription [36]. The receptor’s DNA binding domain (DBD)
is composed of two zinc finger motifs that bind to steroid responsive elements (SREs).
While DBDs are sequence specific, some level of promiscuous association is observed
between DBDs and SREs. The specificity of the receptor-DNA interconnection is dictated
by the presence of multiple SREs and by the interaction with other facilitating proteins
and transcription factors [31,37]. The DBD is connected to the ligand binding domain
(LBD) through the hinge region. The latter is a flexible linker that contains a nuclear
localization signal, contributes to DNA binding and the transcriptional activities of SHRs,
as well as facilitating receptor dimerization and interaction with other proteins [38,39].
The C-terminus encodes the LBD, a well-conserved region among the SHRs [31]. The
LBD contains the AF2 with a conserved helix 12 that undergoes extensive conformational
changes following ligand binding [40].
Steroid hormones possess lipophilic characteristics that allow them to diffuse through
cell membranes and to reach the SHRs in the cytoplasm or nucleus [41]. The binding of
the ligand to the receptor is facilitated by the heat shock protein 90 (HPS90) complex that
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maintains the receptor in an optimal conformation for ligand binding [42]. After interaction
of the ligand with the steroid hormone receptor, the LBD undergoes a conformational
change that results in increased affinity for coregulators, leading to transcription complex
formation [31].
4. Prostate Cancer
Worldwide, PC is the second most commonly diagnosed male cancer with an incidence
of about one in nine men who will develop the disease [43]. The age of diagnosis is mostly
above 60 years and the overall 5-year survival for localized lesions is nearly 100%, which
decreases to about 30% once metastasis occurs [44]. TRIM proteins affect PC in a variety of
ways, acting in a tumor suppressive or oncogenic fashion, reaching from biomarkers for
diagnosis [45] to influencing epithelial mesenchymal transition (EMT) [46] and interactions
with the AR, which will be further explained below.
4.1. TRIMs Involved in Androgen Receptor Biology
Several TRIM proteins are known to interact with the AR including TRIM24, TRIM28
and TRIM68 [47–49]. The first two both belong to the class C-VI TRIM proteins, which con-
tain a plant homeodomain and a bromodomain at their C-terminus. Both of these domains
are epigenetic readers [50], rendering these TRIM proteins capable of transcriptional regula-
tion, which is also reflected in their alternative names as transcription intermediary factor 1
alpha and beta (TRIM24—TIF1α, TRIM28—TIF1β). In addition to these domains, TRIM24
also contains a LxxLL motif that has been described to interact with the AF2 domain of
SHRs including the retinoic acid receptor alpha or the ERα [51,52]. Later it was shown that
TRIM24 also interacts with the AR and enhances the transcriptional output of the AR in a
ligand- and dose-dependent manner that can be further enhanced through interaction with
the histone acetyltransferase TIP60 [47]. In the same study, bromodomain-containing 7 was
identified as an interactor of TRIM24, and overexpression of both proteins reduced AR
activity compared to TRIM24 overexpression alone. This decrease was less evident when
the RING domain of TRIM24 was removed. Interestingly, a mutated TRIM24 lacking the
RING domain localized to the cytosol, whereas the full-length protein was detected in the
nucleus, which suggests that the above-mentioned effect is due to prevented colocalization
of the TRIM24 mutant and the AR. Similar to the effects of TRIM24, TRIM68 displays a
dose-dependent stimulation of androgen response and is associated with AR-coactivators
like TIP60 and p300 in PC cells. In contrast to TRIM24, the RING domain of TRIM68
is required to enhance the AR’s transcriptional activity, and this effect was abrogated
when a proteasomal inhibitor was used. [49]. The above-mentioned observations sug-
gest that substrate ubiquitination and proteasomal degradation are critically involved in
TRIM68-mediated regulation of AR activity.
In PC, androgen deprivation therapy (ADT) is prescribed to block AR signaling, but
relapse is often inevitable. TRIM24 facilitates proliferation under low androgen levels,
which could be a mechanism acting in castration-resistant PC [47,53]. Analysis of the
AR-chromatin-binding landscape in LNCaP-abl (ablated) cells, which can proliferate in the
absence of androgens, revealed that TRIM24 binds to promoters that are critically relevant
for cell proliferation. Genes co-regulated by TRIM24 and AR serve as prognostic markers
for poor outcome and these genes are often highly expressed in metastatic PC [53]. This
cooperativity is further supported by a study in which TRIM24-chromatin-binding sites
were enriched for DNA-consensus motifs for the AR and its pioneer factor FOXA1 [54].
Influence on therapy efficacy has been understudied in relation to TRIM proteins in
PC, but TRIM24 seems to affect the anti-androgen treatment with bicalutamide. Apart from
a pro-proliferative effect of TRIM24 under low androgen levels, TRIM24 also dampens
anti-androgen efficiency. One new mechanism how TRIM24 expression can be regulated
is via the microRNA miR-137. Analyses of several cell lines and tumor samples showed
a negative correlation between TRIM24 and miR-137 expression. As an explanation for
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higher TRIM24 expression in tumor cells, epigenetic silencing of miR-137 via methylation
of promoter proximal CpG islands was suggested [55].
In PC cells, TRIM24 is ubiquitinated and targeted for proteasomal degradation by the
ubiquitin ligase speckle-type POZ protein (SPOP) [56]. SPOP is mutated in roughly 10%
of primary PCs and dominant negative SPOP mutations boost AR signaling [57], as the
mutations impair SPOP to target coregulators of the AR or the AR itself for proteasomal
degradation [58]. However, these results could not explain why TRIM24 levels are higher in
PCs that lack SPOP mutations. More recently, it was reported that TRIM28 is upregulated
in SPOP wild-type tumors and protects TRIM24 from SPOP-mediated degradation [54].
The chromatin interactions of TRIM24 and TRIM28 overlapped to nearly 60%, and these
sites were no longer occupied by TRIM24 upon TRIM28 knockdown. This study also
showed that TRIM28 knockdown reduced overall AR-DNA binding whereas TRIM24
knockdown shifted the AR cistrome to different sites [54]. In general, TRIM28 has a more
diverse chromatin distribution than TRIM24, and with mainly zinc finger and CTCF motifs
being present in the TRIM28 cistrome, it is more likely to be a repressive transcription
factor [59]. Despite this, TRIM28 chromatin interaction profiles also show partial overlap
with AR genome-wide binding patterns, but the TRIM28 chromatin interactions were
independent of androgen stimulation [48]. Consequently, TRIM28 knockdown decreased
colony formation of AR-dependent PC cells and diminished xenograft tumor develop-
ment [54]. The pathways leading to this phenotype can partially be explained by the
TRIM28-AR interactions, as TRIM28 was furthermore reported to facilitate AR activity
in a reporter assay [60]. However, other mechanisms, like EMT, DNA damage response
and p53 degradation that are associated with TRIM28 in other cancers, could also be of
relevance in PC biology (reviewed in [61]).
In addition to the abovementioned TRIM proteins, TRIM36 is also associated with the
AR. TRIM36 is under direct transcriptional control of the AR and is often highly expressed
in PC [62]. However, TRIM36 instead shows tumor suppressive activity in prostate tumors.
On the one hand, TRIM36 overexpression increased expression of proapoptotic genes
like BAX and TNFSF10, enhancing apoptotic signaling [63]. On the other hand, TRIM36
knockdown activated MAPK/ERK signaling [64], with increased phosphorylation of ERK.
In line with the antiproliferative effects of TRIM36, overexpression of this protein syner-
gized with ADT to reduce growth of LNCaP cells. Since TRIM36 is a direct AR-responsive
gene, the AR/TRIM36 connection may function as a negative feedback mechanism [65].
Nonetheless, TRIM36 may still be lowly expressed in PC despite active AR signaling,
which could be mediated through TRIM36 promoter hypermethylation, as it has been
reported in ovarian cancer (OC) and neuroblastoma [66,67]. In a recent preprint, TRIM59
was found to be under direct transcriptional control of the AR as well [68]. In contrast to
TRIM36, the activated AR represses TRIM59 expression. This regulatory mechanism was
investigated in the light of treatment-induced neuroendocrine prostate cancer (t-NEPC),
where treatment with AR-inhibiting drugs resulted in an upregulation of TRIM59 that
showed to be important for xenograft growth in LAPC4 and DU-145 cell lines. Further-
more, the authors linked the growth advantages of TRIM59-overexpressing LNCaP and
LAPC4 cells to post-translational downregulation of RB1 and p53 in combination with
SOX2 overexpression, which seemed critical for the t-NEPC phenotype [68]. In earlier
work, TRIM59 has been associated with androgen-independent growth, which it stimulates
by upregulation of general pro-proliferative proteins like cyclins and their respective cyclin-
dependent kinases. For TRIM59, it was found that knockdown increased the percentage of
cells residing in G0/G1 or S phase as opposed to G2/M, linking TRIM59 with cell cycle
progression, which was further supported by reduced protein levels of Cyclin B1 and Cdc2
upon TRIM59 knockdown. Furthermore, TRIM59 is expressed at higher levels in cancerous
tissue compared to the adjacent normal tissue, and in vitro and xenograft studies showed
that reduced TRIM59 levels diminished cellular proliferation rate and colony formation of
PC-3 and DU-145 cells [69].
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4.2. TRIMs and AR-Independent Signaling Pathways
Even though PC is strongly driven by the AR, many other mechanisms facilitate tumor
cell proliferation and enhance metastatic potential, especially in metastatic castration-
resistant PC. Known pathways for androgen-independent proliferation are, for example,
MAPK signaling, deregulation of cytokines or PI3K/Akt signaling [64].
In addition to the abovementioned perturbations, the altered expression of TRIM
proteins can also promote PC independent of AR signaling, such as TRIM44. In a set
of knockdown experiments in AR-negative PC-3 cells, proliferation and migration were
reduced upon TRIM44 knockdown. These effects were associated with changes in the
phosphorylation status of PI3K and Akt, as TRIM44 knockdown decreased the levels of the
phosphorylated variants [70]. How these changes are linked to TRIM44 biology and how
TRIM44 is regulated in tumors was not investigated.
A cytokine-related pathway that is affected by TRIM proteins is the JAK/STAT signal-
ing axis, which is controlled by TRIM66. Upon TRIM66 knockdown in PC-3 and DU-145
cells, proliferation was decreased, which was attributed to downregulation of STAT2 and
IL-2 [71]. However, the exact mechanism remains unknown. As TRIM66 belongs to the
TIF1 family, it can be speculated that TRIM66 alters expression of target genes directly. An-
other member of the TIF1 family is TRIM33, which is reported to act on EMT, as epithelial
markers were found downregulated upon shRNA-mediated knockdown of TRIM33. This
positive regulation of epithelial proteins could be a possible mechanism for the effect of
valproic acid on EMT inhibition in PC, as valproic acid induces TRIM33 expression [72].
Similarly, TRIM16 is lowly expressed in prostate tumors in comparison to healthy prostate
epithelial cells and negatively regulates EMT. However, the mechanism of TRIM16 action
in PC is different from the other TRIM members described above and has been linked to
the EMT-driving transcription factor Snail, which is reduced in cells with higher levels of
TRIM16 [46].
A more thoroughly studied TRIM that acts independently of the AR is TRIM25. A
study in LNCaP and 22Rv1 cells, which was further validated by 22Rv1 xenograft mouse
experiments, showed that TRIM25 is essential for the complex formation of p53 and the
GTPase-activating protein-binding protein 2 (G3BP2). This complex subsequently recruits
the SUMO-ligase RanBP2, resulting in p53 SUMOylation and export from the nucleus [73].
This effect increased migration and proliferation in PC cells as p53-dependent mechanisms
like senescence or apoptosis were reduced [74]. An analysis of patient data showed that
TRIM25 is upregulated in cancerous lesions and serves as a negative prognostic factor
for survival. In line with these findings, knockdown of TRIM25 reduced tumor cell
proliferation in vitro and in vivo. Interestingly, the RING domain of TRIM25 was not
required for the interaction with G3BP2, as a TRIM25-truncation mutant showed similar
effects as compared to the wild-type protein [73]. However, the RING domain is needed
for proteasomal degradation of the transcription factor ERG (ETS related gene). ERG
drives PC cell proliferation and is often found to be fused to the AR-responsive TMPRSS2
gene, which leads to aberrant expression and activity of ERG and malignant growth of
prostate cells [75]. Interestingly, TRIM25 is a target gene of ERG and thereby contributes to
a negative feedback loop controlling ERG levels. In tumors with overexpressed TRIM25,
the deubiquitinase USP9x removes the TRIM25-mediated polyubiquitin chain from ERG to
prevent its degradation even when TRIM25 is overexpressed through ERG fusions [76].
A unique TRIM protein in regard of function is TRIM19, which is better known as
promyelocytic leukemia protein (PML). In the nucleus, TRIM19 oligomerizes and forms
spherical nuclear bodies (TRIM19-NB or PML-NB), which can be seen as speckles in im-
munofluorescence microscopy and have properties of a liquid−liquid phase separation
nonmembrane compartment (reviewed in [77]). These TRIM19-NBs are dynamic structures
that are involved in several cancer-related mechanisms including alternative lengthen-
ing of telomers (ALT), p53-induced senescence, inhibition of Akt signaling or chromatin
and SUMOylation dynamics (reviewed in [77,78]). TRIM19 was previously identified
as a tumor-suppressive protein in overexpression studies in different PC cell lines [79].
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Several translational studies reported that TRIM19 is often misregulated in PC directly,
when co-lost with PTEN, forcing a more aggressive growth than the otherwise indolent
PTEN-only deficient tumors [80–82], or indirectly via deregulation of TRIM19 coregula-
tors. For the latter, it has been shown that proteins that force TRIM19-NB disintegration
through post-translational modifications of TRIM19 blunt the otherwise pro-senescence
signaling of TRIM19-NBs. Those tumors have higher proliferation rates and worse clinical
outcome [83–87]. In relation to AR biology, there is only limited evidence of TRIM19 func-
tion, but some results show that TRIM19 can be downregulated upon AR stimulation in
CWR22R cells [88]. Moreover, the AR status is an important determinant of TRIM19-driven
ALT, which drives AR-independent cell proliferation [89].
5. Breast Cancer
With the highest incidence rates of all cancer types in women, BC affects over two
million women worldwide [43]. BC is highly heterogeneous in its etiology, with dis-
tinct intrinsic subtypes that depend on divergent molecular pathways that drive tumor
cell proliferation [90]. TRIM proteins are known to play a role in BC proliferation and
progression [91–93] and can function as biomarkers for prognostication and disease pro-
gression [94–96].
5.1. The Role of TRIMs in BC Tumor Growth and Proliferation
75% of BC cases are ERα-positive [34], and these tumors are generally thought to
be critically dependent on the activity of this hormone-driven transcription factor [97].
TRIM24 and TRIM56 were found to interact with ERα, stabilizing its chromatin interactions,
thereby enhancing estradiol-stimulated tumor cell proliferation [91,93]. In fact, both TRIMs’
aberrant overexpression in BC is correlated with poor survival of BC patients, and depletion
of these TRIMs leads to reduced cell proliferation, as has been shown for tumor-derived
BC cells for TRIM24 [91] and MCF7 cells for TRIM56 [93].
Despite the clinical success of current BC treatments, around 30% of BC patients will
develop metastatic disease [98]. Since targeted treatment options are still lacking for these
patients, growing efforts are needed to identify new molecular targets to improve treatment
options in the metastatic setting.
Firstly known as estrogen-responsive finger protein, TRIM25 is a downstream tran-
scriptional target of ERα [99,100] and was previously shown to be essential for estrogen-
dependent cell proliferation [101]. TRIM25 expression is associated with poor prognosis in
BC patients [102]. Furthermore, TRIM25 is associated with BC subtype and is significantly
higher expressed in ERα-negative basal BCs. Remarkably however, TRIM25 did not appear
under direct transcriptional control of ERα in other studies [103,104]. In fact, overexpres-
sion of TRIM25 in ovariectomized athymic mice (absence of estrogens) is still capable of
generating tumors. Treatment with an antisense TRIM25 oligonucleotide led to impaired
growth of MCF7 tumors implanted in female athymic mice due to an accumulation of
14-3-3σ protein, a G2 cell cycle arrest inducer. It was shown that TRIM25 downregulates
14-3-3σ by acting as an E3 ligase, recruiting the E2 UBCH8 to ubiquitinate the 14-3-3σ
protein and lead it to proteasomal degradation [104]. TRIM25 was also reported to regulate
key stemness genes including POU5F1, NANOG and SOX2, promoting cell migration and
contributing to BC metastasis formation [103,105].
TRIM59 was found overexpressed in human breast cancer samples, compared to
paired nontumor samples, and was associated with poor prognosis for these BC pa-
tients [96]. Furthermore, knockdown of TRIM59 in MCF7 cells reduced cell prolifera-
tion in vitro and in vivo, while TRIM59 expression in MDA-MB-231 cells (which express
low endogenous levels of TRIM59) enhanced cell proliferation [96]. TRIM28 was also
found overexpressed in BC and plays an important role in promoting metastatic dis-
ease [92,106,107], as TRIM28 depletion decreased the growth and metastatic potential
of tumor xenografts [92]. Moreover, TRIM28 was shown to interact directly with the
metastasis-associated transcription factor TWIST1. TRIM28 stabilizes TWIST1, possibly by
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preventing its ubiquitination [106]. However, as these findings are not yet conclusive, addi-
tional research needs to be performed to confirm the biological impact of TRIM28−TWIST1
interaction in metastatic BC progression.
Expression of TRIM13 and TRIM21 is decreased upon BC tumorigenesis and this
decreased expression is correlated with poor outcome [95,108]. TRIM21 depletion in
ERα-positive BC cell lines MCF7 and T47D increased Snail protein levels and increased
cell migration and invasion, with opposite effects observed when TRIM21 was over-
expressed [109]. This effect is explained by increased ubiquitination and proteasomal
degradation of Snail in the presence of TRIM21. Thus, TRIM21 seems to regulate metastatic
transformation of BC cells by regulating Snail protein ubiquitination. TRIM16 levels were
also reduced in BC tissue samples compared to the matched normal adjacent breast tissue
and its expression is negatively correlated with metastatic progression of BC patients [110].
TRIM19 (PML) was found overexpressed in triple-negative BC and correlated with
reduced disease-free survival and poor prognosis for patients [111]. TRIM19 inhibition
led to impaired cell proliferation and decreased cell cycle progression in triple-negative
BC cells [112,113], demonstrating a drug target potential for TRIM19 to treat this subtype
of the disease. In ERα-positive BC cell lines (MCF7 and T47D), TRIM19 protein levels
were significantly lower as compared to triple-negative BC cell lines [111,113]. Finally,
TRIM19 was found to interact with ERα in MCF7 cells and tumors from ERα-positive
patient-derived xenografts and ERα-positive human BC tumor samples [114]. Further
research would be required to better understand the role of TRIM19 in ERα biology.
5.2. TRIMs in BC Development, Progression and Prognosis
Numerous TRIMs were found to be overexpressed in breast tumors, compared to
normal breast tissue: TRIM11, TRIM32, TRIM33, TRIM37, TRIM39, TRIM44, TRIM47 and
TRIM63 [94,115–120]. TRIM37 overexpression in MCF7 cells led to the silencing of several
tumor suppressor genes through H2A monoubiquitination, an epigenetic marker of tran-
scriptional repression. Interestingly, ectopic expression of TRIM37 increased proliferation
of MCF10AT cells (a premalignant MCF10A cell line, stably expressing HRAS) in vitro and
tumor formation in vivo. These results suggest a role of TRIM37 in BC tumorigenesis by
silencing tumor suppressor genes [117].
TRIM33 expression was firstly described as decreased in breast tumors, compared
to normal breast tissues [121]. However, another study revealed that TRIM33 expression
was increased in nearly 40% of BC patients, and its overexpression was related to poor
prognosis [122]. Thus, further studies should be performed to fully understand the role of
TRIM33 in BC.
6. Ovarian Cancer
Ovarian cancer (OC) is a very challenging gynecologic disease, partly due to the
late diagnosis that usually occurs, with symptoms appearing at a late stage of cancer
progression [123]. Even though its incidence has decreased in recent years, OC is still
associated with the highest death rate of all gynecological cancers [124].
62% of OCs are considered hormone-responsive cancers, with ERs (both ERα and
ERβ) playing a predominant role in their development and progression [125]. While ERα
expression is increased in at least a subset of ovarian tumors compared to normal ovarian
tissue, ERβ is progressively lost during cancer progression [126].
Different TRIM proteins have been reported to play a role in OC. Two of them (TRIM16
and TRIM50) are considered tumor suppressive [127–130], while others (TRIM11, TRIM25,
TRIM27, TRIM52 and TRIM59) instead promote oncogenesis in this type of cancer [131–136].
To date, only TRIM25 has been studied in relation to ERs in OC [137].
6.1. Tumor Suppressive TRIMs
TRIM16 was found overexpressed in ER-positive ovarian serous papillary cancers
compared to normal tissue [127]. However more recently, TRIM16 was also found to
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reduce migration and invasion of epithelial OC cells (SKOV3 and OVCAR3) in vitro. In
these in vitro models, TRIM16 inhibited EMT by upregulating E-cadherin protein levels
(a well-known epithelial marker) and downregulating mesenchymal markers such as
N-cadherin and vimentin [128,138]. Overexpression of TRIM16 in SKOV3 cells also down-
regulated protein levels of the matrix metalloproteases MMP2 and MMP9, which degrade
the extracellular matrix, indicating a role of TRIM16 in cancer cell invasion [139]. TRIM16
furthermore inhibited the hedgehog signaling cascade, including sonic hedgehog (Shh),
smoothened (SMO), patched (PTCH), and the glioma-associated oncogene homolog-1 (GLI-
1) [128]. Shh signaling positively regulates GLI-1 transcription factors in the development
of different types of cancer, including OC. After GLI-1 activation through Shh signaling,
GLI-1 stimulates EMT in OC cells, enhancing the migration and invasion abilities of SKOV3
cells [129]. A decreased invasive phenotype of BC and hepatocellular carcinoma cells can
be caused by the inhibition of MMP2 and MMP9 expression upon suppression of Shh
signaling [140,141]. Similarly, TRIM16 may inhibit the migration and invasion abilities of
OC cells by downregulating MMP2 and MMP9 through inhibition of the Shh signaling
pathway [128].
Gain- and loss-of-function experiments in SKOV3 and A2780 cell lines have also
demonstrated that TRIM50 is required for proliferation and migration of OC cells in vitro,
as well as for tumor growth in xenograft models in vivo [130]. Low levels of TRIM50
were correlated with higher pathological grades, advanced FIGO (International Federation
of Gynecology and Obstetrics) stages and increased lymph node metastasis formation
in patients with OC [130]. The tumor suppressive function of TRIM50 is, at least partly,
explained by TRIM50-mediated ubiquitination and proteasomal degradation of Src, a
proto-oncogene whose expression is correlated with poor prognosis in multiple cancer
types [130,142].
6.2. TRIMs That Promote Proliferation and Metastasis of OC
Multiple TRIM proteins have been reported as being functionally relevant in OC
cell proliferation and migration. TRIM27 has been implicated in OC in multiple studies,
being higher expressed in cancer samples compared to normal ovarian tissue and higher
expressed in cancer cell lines in comparison to untransformed cells [133–135]. Further-
more, high expression of TRIM27 in OC was associated with poor prognosis [133–135].
Interestingly, downregulation of TRIM27 sensitized the OC cell lines SKOV3 and HEY
to carboplatin- or paclitaxel-induced apoptosis, which could be confirmed in mouse
xenografts. Taken together, these results imply that TRIM27 could be targeted to enhance
the chemosensitivity of OC to carboplatin and paclitaxel [133]. Silencing of TRIM27 in
SKOV3 and OVCAR3 cells reduced proliferation and the colony-forming ability of cells, as
well as increasing their apoptosis rate (SKOV3 cells), indicating that knockdown of TRIM27
may induce cell cycle arrest and apoptosis [135]. Furthermore, knockdown of TRIM27
increased the number of cells in S-phase of the cell cycle and upregulated the protein levels
of p-ATR and p-Chk1 (both required for the S-phase checkpoint [143]). ATR participates in
cell cycle arrest by phosphorylating and activating Chk1, which can phosphorylate target
proteins such as p53 and trigger cell cycle arrest [144]. Taken together, these results indicate
that TRIM27 knockdown could induce S-phase arrest [135]. An increased number of cells
in the S-phase could also explain the enhanced sensitivity of OC cells to chemotherapeutics,
as cells are generally susceptible to chemotherapy when they are in the S-phase of their
cell cycle [145]. Downregulation of TRIM27 also increased phosphorylation of p38 and
decreased phosphorylation of Akt in SKOV3 and OVCAR3 cells. p38 and Akt are members
of the MAPK and PI3K-Akt pathways, respectively, which are linked to cell proliferation,
differentiation and apoptosis [146,147]. The regulation of the abovementioned cascades
by TRIM27 suggests a role of TRIM27 in cell proliferation- and apoptosis-related path-
ways [135]. TRIM27 is under miRNA regulation, as miR-383-5p targets the 3′-UTR of
TRIM27 mRNA leading to TRIM27 downregulation. miR-383-5p-mediated silencing of
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TRIM27 resulted in inhibition of OC cell proliferation, as well as enhanced chemosensitivity
to paclitaxel treatment through regulation of the PI3K/Akt pathway [134].
Two independent studies on TRIM59 in OC indicated that TRIM59 is higher expressed
in cancerous tissues compared to normal specimens, with high TRIM59 levels being asso-
ciated with poor prognosis and unfavorable relapse-free survival [131,132]. Both studies
observed a reduction in proliferation and migration of OC cells upon silencing of TRIM59.
Further analyses of the molecular mechanisms of these regulations identified binding of
Annexin A2 to TRIM59 [131]. Annexin A2 was previously described as a prognostic factor
in OC [148]. This study also showed that TRIM59 positively regulates Annexin A2 protein
expression [131]. On the other hand, TRIM59 was implicated in the FAK/Akt/matrix
metalloproteases signaling pathway [132], which enhances metastatic features of tumors,
including cell survival, proliferation, migration and invasion [149].
TRIM11 was also found upregulated in OCs compared to adjacent normal tissues [150].
Knockdown of TRIM11 reduced proliferation of A2780 and SKOV3 cells, which was
ascribed to decreased Bcl-2 and induction of BAX protein levels upon TRIM11 knockdown.
TRIM11 may furthermore be involved in the invasion of OC cells, as downregulation
of TRIM11 suppressed MMP2 and MMP9 protein levels [150]. TRIM11 also reduced
phosphorylation of ERK and Akt, both of which are involved in the regulation of Bcl-2 and
MMP family members [151,152]. By controlling ERK and Akt activity, TRIM11 might lead
to deregulation of Bcl-2 and MMP proteins [150–152].
Analysis of RNA-seq data from the TCGA database highlighted a significantly higher
expression of TRIM52 in ovarian cancerous tissues compared to normal tissues [136].
Overexpression of TRIM52 in H08910 cells increased cell proliferation, migration and
invasion, while knockdown of TRIM52 in SKOV3 and CAOV3 cells reduced cellular
migration, invasion and proliferation, yet enhanced apoptosis [136]. TRIM52 was positively
correlated with transcript levels of p65, a subunit of the NF-κB complex, in OC specimens.
NF-κB downstream effectors were also regulated upon silencing of TRIM52 in SKOV3 and
CAOV3 cells. ShRNA-mediated suppression of TRIM52 resulted in downregulation of
MMP9, Bcl-2, IL-8 and TNFα protein levels, whilst the protein levels of caspase-3 were
upregulated. The opposite phenotype was observed after overexpression of TRIM52 in the
HO8910 cell line [136].
As described above for PC and BC, TRIM19 (PML) has also been investigated in OC.
ShRNA-mediated TRIM19 downregulation decreased cell proliferation and colony forma-
tion and increased apoptosis and cleavage of caspase-3 in OV2008 cells [153]. TRIM19 was
also shown to accumulate in the nucleus of OV2008 cells upon X-ray irradiation and colo-
calized with DAXX, a well-established transcriptional regulator [153,154]. TRIM19-DAXX
nuclear bodies were described as highly dynamic structures, whose number increased after
DNA damage, as shown by the treatment of ES-2 cells with bleomycin [154]. In support of
these findings, reduced TRIM19 expression resulted in increased γ-H2AX phosphorylation
(an early step in the DNA damage response [155]), whilst TRIM19-DAXX nuclear bodies
partially colocalized with γ-H2AX. Altogether, these results indicate that TRIM19, together
with DAXX, can have a protective effect on cells after DNA damage [153,154].
6.3. Other TRIMs
Analogous to BC and PC, TRIM25 has also been associated with OC, being highly
expressed in 63% of OC tissues analyzed and associated with a more advanced stage of the
disease [137].
For many of the TRIM proteins described in this section only SHR-independent
mechanisms have been proposed. However, a possible interplay of these TRIM proteins
with SHRs cannot be excluded, although no such findings have been reported to date.
7. Endometrial Cancer
According to the GLOBOCAN estimates in 2020, endometrial cancer (EC) is the third
most common and the fourth most fatal gynecological cancer in women worldwide [43].
Cells 2021, 10, 1517 10 of 19
The majority of EC cases express high levels of ERα and ERβ, while less than 40% of the
cases show positivity for PR (PR-A and PR-B). Typically, EC cases with positivity for ERα,
PR-A and PR-B relate to low grade tumors with a favorable disease-specific survival [156].
TRIMs in EC
Four TRIM proteins have been related to EC: TRIM22, TRIM25, TRIM27 and TRIM44 [157–162].
TRIM22 expression was reported to be downregulated in EC samples compared to normal
endometrial tissues, and low TRIM22 expression was found to be associated with a high
clinical stage of the disease [157]. In the same study, TRIM22 decreased proliferation and
migration of KLE, Ishikawa and RL-952 EC cells in vitro and inhibited tumor growth
in xenograft models in vivo [157]. These effects are explained by increased levels of the
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) protein upon
TRIM22 overexpression in Ishikawa cells [157]. The role of NOD2 in cancer is controversial
and may depend on the type of cancer considered. However, NOD2 has been involved
in the regulation of numerous cellular pathways including NF-κB-, PI3K- and MAPK-
cascades [163]. In the study published by Zhang and coworkers, TRIM22 increased not
only NOD2 protein levels but also the protein levels of NF-κB-p65 and IκBα, while their
phosphorylation was reduced, resulting in diminished NF-κB signaling [157]. As a parallel
effect, TRIM22 also inhibited the activity of NF-κB by preventing the translocation of
the p65 subunit into the nucleus. Both mechanisms strongly reduced NF-κB activity and
inhibited EC progression [157,164]. In agreement with the findings in BC [165], TRIM22
was under direct transcriptional control of PR-A in EC cells, which was mediated by a
direct association of PR-A with the progesterone responsive element in the 5′-upstream
region of TRIM22. As progesterone and its analogues are an effective treatment for patients
with EC [166], these data suggest that TRIM22 may contribute to the anticancer effects of
progesterone in EC [158]
More controversial are the results published for TRIM25 in EC. TRIM25 expres-
sion levels were found to be decreased in endometrial tumors relative to healthy tis-
sue [159,161,167]. Moreover, TRIM25 was positively correlated with expression of ERα and
PR [159]. Although the data collected in vivo suggested that the effect of TRIM25 on EC
could be linked to ERα signaling, in vitro experiments showed that this is not the case. Two
independent studies showed a decreased growth rate upon downregulation of TRIM25 in
both ERα+ and ERα- EC cell lines, regardless of whether they were treated with estrogens
or not [160,161]. Furthermore, TRIM25 downregulation reduced migration of EC cells in
the absence of hormone treatment and stopped tumor growth in xenograft mouse models,
suggesting that TRIM25 may slow down the transformation process in EC, independently
of ERα signaling [160,161].
Different mechanisms have been proposed to explain the role of TRIM25 in the progres-
sion of EC. On the one hand, TRIM25 was required for estrogen-dependent activation of vas-
cular endothelial growth factor (VEGF), an important regulator of angiogenesis [160,168].
On the other hand, downregulation of TRIM25 was associated with increased levels of 14-
3-3σ protein, both in vitro and in vivo [104]. At the same time, a reporter assay conducted
in HEC-1A and Ishikawa cells showed that TRIM25 induced the transcriptional activity of
NF-κB [161], whose deregulation is linked to the malignant progression of a large number
of cancers, including EC [169]. In agreement with the regulation of NF-κB by TRIM25,
TRIM25 knockdown resulted in transcriptional downregulation of NF-κB downstream
effectors, including STAT3, STAT5, IFN-γ, IFN-α, interleukin 6 signal transducer (IL6ST)
and IL18 [161]. Taken together, TRIM25 is implicated in the progression of EC by enhancing
NF-κB signaling, in addition to the downregulation of 14-3-3σ protein.
In contrast to the TRIMs described above, TRIM44 and TRIM27 have been correlated
to a malignant phenotype in EC. TRIM44 expression was found upregulated in EC relative
to normal endometrial tissue and correlated to high FIGO stages, high histological grades
and lymph node metastases [162]. TRIM44 protein levels were also found associated
with poor overall survival of EC patients [162]. Similarly, TRIM27 was correlated to poor
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prognosis in patients with EC [170]. Furthermore, TRIM27 was also described to facilitate
migration and invasion of EC cells in vitro through a process that involves at least the
decrease of the protein levels of ITGB1, ITGA2 and ITGA5, three integrins implicated in
cancer progression [170,171].
8. Discussion
SHR-driven cancers are amongst the most commonly diagnosed tumor types and are
usually sex specific. As for practically all cancers, advances in earlier detection together
with improved treatment schemes allowed for decreased mortality while the incidence
increased [172]. Today, cancer is still the second leading cause of death worldwide, and
roughly 9.9 million patients succumbed to the consequences of cancer in 2020 [43]. In the
case of SHR-positive cancers, their ligand-dependent nature provides a unique opportunity
for pharmaceutical intervention, and hormonal therapies represent the first and most
successful treatments in cancer care. Nonetheless, as the development of resistance to
hormonal intervention is common, alternative therapeutic strategies are urgently needed
to improve the outcome for these patients. A better understanding of the fundamental
biological processes involved in hormone receptor biology would allow a bottom-up
approach to link molecular mechanisms to phenotypes and the revelation of possible novel
therapeutic avenues in case of endocrine resistance.
TRIM proteins are a group of proteins with diverse activities, grouped by structural
properties instead of function. As a consequence, TRIMs expose a plethora of molecular
functions, some of them being involved in cancer-related processes. Across the board
of the investigated cancer subtypes, TRIM proteins affect major pathways specific to
cancer (Figure 1). For example, TRIM24 controls AR-driven transcriptional regulation in
PC [47,53,56] but also general cancer mechanisms including EMT [128]. As it is feasible
to design small molecule inhibitors for TRIM protein family members, as has already
been established for TRIM24 [173], therapeutic development programs may be of high
importance to increase the druggable space for hormone-driven cancers.
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Though of clinical and translational interest, many TRIM proteins are understudied in
their molecular function and are often only explored in a single tumor type while it remains
to be established whether the observations made in one particular setting could reliably
be transposed to another. This partial and context-dependent molecular understanding
results in the current situation, in which the scientific community is faced with a patchwork
of knowledge that needs to be further expanded and unified. Even though some TRIM
proteins, like TRIM25, have been studied in numerous cancers and show a similar overall
oncogenic function, the underlying mechanisms in which TRIM25 is involved are different,
acting as a p53 regulator in PC [73] but as a driver for metastasis in breast cancer [103]
(Figure 2). Thus, particular TRIM proteins can play diverse roles in cancer cell biology,
which appear to be context-dependent. Therefore, future studies should include extensive
molecular and mechanistic analyses in the context of different cancer types, which may
reveal both context-dependent as well as more general ubiquitous functions of TRIM
proteins. For example, TRIM16 has been associated with EMT in prostate [46], breast [110]
and ovarian cancer [128], and an association with Snail regulation has been shown for
the first two cancer types. This conserved biological functioning of TRIM16 suggests a
commonly shared mode-of-action and positions TRIM16 as a negative regulator of EMT,
irrespective of the biological context.
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In BC and PC, many of the TRIM proteins act independently of AR or ERα and have
been associated with regulator functions for central cancer-related pathways including
EMT or apoptosis. These general associations are also seen in other cancers, as reviewed
previously [1,4]. However, knowledge from PC on the class C-VI of TRIM proteins and
their interaction with AR might be translatable and useful in ERα-driven cancer types.
Furthermore, the protein-specific bromodomain present in these proteins allows targeting
of these proteins with functional degraders like PROTACS, which has been shown for
TRIM24 [174]. This could lead to the discovery of new potential therapeutics, in which the
Cells 2021, 10, 1517 13 of 19
structural similarities between TRIM proteins would represent a major challenge and may
come at the cost of a certain level of cross-reactivity within the protein family.
In general, our current understanding on TRIM function in different contexts of on-
cology, the exact mode of regulation of the TRIMs described in this study and how this
deviates between tumor cells relative to normal cells remains far from complete and many
studies remain at present associative, lacking deep mechanistical insights. As TRIM pro-
teins act on multiple critical nodes of steroid hormone-dependent carcinogenesis and tumor
progression, a deeper mechanistic understanding of TRIM action is critical to fully exploit
the clinical potential of TRIMs as drug targets and biomarkers for treatment selection. With
the efforts to date, we are still in the early stages of fundamental, pharmaceutical and
clinical research on this highly interesting yet complex protein family.
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